1.Current treatment status and medical costs for hemodialysis vascular access based on analysis of the Korean Health Insurance Database.
Hyung Seok LEE ; Young Su JU ; Young Rim SONG ; Jwa Kyung KIM ; Sun Ryoung CHOI ; Narae JOO ; Hyung Jik KIM ; Pyoungju PARK ; Sung Gyun KIM
The Korean Journal of Internal Medicine 2018;33(6):1160-1168
BACKGROUND/AIMS: The Republic of Korea is a country where the hemodialysis population is growing rapidly. It is believed that the numbers of treatments related to vascular access-related complications are also increasing. This study investigated the current status of treatment and medical expenses for vascular access in Korean patients on hemodialysis. METHODS: This was a descriptive observational study. We inspected the insurance claims of patients with chronic kidney disease who underwent hemodialysis between January 2008 and December 2016. We calculated descriptive statistics of the frequencies and medical expenses of procedures for vascular access. RESULTS: The national medical expenses for access-related treatment were 7.12 billion KRW (equivalent to 6.36 million USD) in 2008, and these expenses increased to 42.12 billion KRW (equivalent to 37.67 million USD) in 2016. The population of hemodialysis patients, the annual frequency of access-related procedures, and the total medical cost for access-related procedures increased by 1.6-, 2.6-, and 5.9-fold, respectively, over the past 9 years. The frequency and costs of access care increased as the number of patients on hemodialysis increased. The increase in vascular access-related costs has largely been driven by increased numbers of percutaneous angioplasty. CONCLUSIONS: The increasing proportion of medical costs for percutaneous angioplasty represents a challenge in the management of end-stage renal disease in Korea. It is essential to identify the clinical and physiological aspects as well as anatomical abnormalities before planning angioplasty. A timely surgical correction could be a viable option to control the rapid growth of access-related medical expenses.
Administrative Claims, Healthcare
;
Angioplasty
;
Arteriovenous Fistula
;
Endovascular Procedures
;
Humans
;
Insurance
;
Insurance, Health*
;
Kidney Failure, Chronic
;
Korea
;
Observational Study
;
Renal Dialysis*
;
Renal Insufficiency, Chronic
;
Republic of Korea
2.Risk Factors for Development and Recurrence of Peptic Ulcer Disease.
Jin Joo KIM ; Nayoung KIM ; Byoung Hwan LEE ; Jung Mook KANG ; Pyoungju SEO ; Min Kyoung LIM ; Jung Hee KWON ; Byeong Jun SONG ; Jung Won LEE ; Sang Hyup LEE ; Young Soo PARK ; Jin Hyeok HWANG ; Jin Wook KIM ; Sook Hyang JEONG ; Dong Ho LEE ; Hyun Chae JUNG ; In Sung SONG
The Korean Journal of Gastroenterology 2010;56(4):220-228
BACKGROUND/AIMS: Peptic ulcer disease (PUD) is one of the common gastrointestinal diseases, and its medical management has been developed so much that the incidence of its serious complications, such as bleeding and perforation, are declining significantly. Its prevalence in Korea is not definitely decreased, probably due to increasing proportion of elderly patients and their rising usage of non-steroidal anti-inflammatory drugs (NSAIDs) and aspirins. This study was conducted to identify the risk factors for development and recurrence of peptic ulcer disease in Korea. METHODS: From 2003 to 2008, upper gastrointestinal endoscopy and detailed personal questionnaires were performed for patients who visited Department of Gastroenterology at Seoul National University Bundang Hospital. In total, 475 PUD patients and 335 non-ulcer dyspepsia patients were included. The results of questionnaires and repeated upper gastrointestinal endoscopy at initial diagnosis time and follow-up periods were analyzed. RESULTS: Multivariable analysis showed that male, H. pylori infection, NSAIDs use and smoking were risk factors for the development of PUD. The use of proton pump inhibitors (PPIs) and H2 receptor antagonists has significantly reduced the risk of PUD in patients who had taken NSAIDs and/or aspirins. H. pylori infection was found as the only risk factor for the recurrence of PUD. CONCLUSIONS: For the old patients who are taking drugs, such as NSAIDs and aspirins, concomitant use of PPIs or H2 receptor antagonists should be considered to protect from the development of PUD. H. pylori eradication has been confirmed again to be essential for the treatment of PUD patients infected with H. pylori.
Adult
;
Aged
;
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
;
Aspirin/therapeutic use
;
Endoscopy, Gastrointestinal
;
Female
;
Helicobacter Infections/complications/drug therapy
;
Helicobacter pylori
;
Histamine H2 Antagonists/therapeutic use
;
Humans
;
Male
;
Middle Aged
;
Peptic Ulcer/drug therapy/*etiology
;
Proton Pump Inhibitors/therapeutic use
;
Questionnaires
;
Recurrence
;
Risk Factors
;
Sex Factors
;
Smoking
;
Stomach Ulcer/etiology